Resultats de la cerca - Issa, Samar

Carbazole scaffolds in cancer therapy: a review from 2012 to 2018 per Issa, Samar, Prandina, Anthony, Bedel, Nicolas, Rongved, Pål, Yous, Saïd, Le Borgne, Marc, Bouaziz, Zouhair

Obtenir text complet Obtenir text complet Obtenir text complet

Regulation of microRNAs in Cancer Metastasis per Bouyssou, Juliette M.C., Manier, Salomon, Huynh, Daisy, Issa, Samar, Roccaro, Aldo M., Ghobrial, Irene M.

Obtenir text complet Obtenir text complet Obtenir text complet

MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma per van der Meulen, Matthijs, Dirven, Linda, Bakunina, Katerina, van den Bent, Martin J., Issa, Samar, Doorduijn, Jeanette K., Bromberg, Jacoline E. C.

Obtenir text complet Obtenir text complet Obtenir text complet

NCOG-05. IMPACT OF ADDITIONAL RITUXIMAB TO STANDARD THERAPY ON COGNITIVE PERFORMANCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS per van der Meulen, Matthijs, Dirven, Linda, Habets, Esther, Bakunina, Katerina, Taphoorn, Martin, van den Bent, Martin, Issa, Samar, Doorduijn, Jeanette K, Bromberg, Jacoline E C

Obtenir text complet Obtenir text complet

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project per Bromberg, Jacoline E., Doorduijn, Jeanette K., Illerhaus, Gerald, Jahnke, Kristoph, Korfel, Agniezka, Fischer, Lars, Fritsch, Kristina, Kuittinen, Outti, Issa, Samar, van Montfort, Cees, van den Bent, Martin J.

Obtenir text complet Obtenir text complet Obtenir text complet

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY P... per Soussain, Carole, Grommes, Christian, Issa, Samar, Ward, Renee, Peterson, Caryn, Cravets, Matt, Mathias, Anita, Sosa, Judith, Kirby, Brian, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark, Steinberg, Marcos, Tun, Han W

Obtenir text complet Obtenir text complet

Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI per Wieduwilt, Matthew J., Valles, Francisco, Issa, Samar, Behler, Caroline M., Hwang, James, McDermott, Michael, Treseler, Patrick, O’Brien, Joan, Shuman, Marc A., Cha, Soonmee, Damon, Lloyd E., Rubenstein, James L.

Obtenir text complet Obtenir text complet Obtenir text complet

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Fo... per Flinn, Ian W., van der Jagt, Richard, Kahl, Brad, Wood, Peter, Hawkins, Tim, MacDonald, David, Simpson, David, Kolibaba, Kathryn, Issa, Samar, Chang, Julie, Trotman, Judith, Hallman, Doreen, Chen, Ling, Burke, John M.

Obtenir text complet Obtenir text complet Obtenir text complet

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study per Flinn, Ian W., van der Jagt, Richard, Kahl, Brad S., Wood, Peter, Hawkins, Tim E., MacDonald, David, Hertzberg, Mark, Kwan, Yiu-Lam, Simpson, David, Craig, Michael, Kolibaba, Kathryn, Issa, Samar, Clementi, Regina, Hallman, Doreen M., Munteanu, Mihaela, Chen, Ling, Burke, John M.

Obtenir text complet Obtenir text complet Obtenir text complet

Extent of radiological response does not reflect survival in primary central nervous system lymphoma per van der Meulen, Matthijs, Postma, Alida A, Smits, Marion, Bakunina, Katerina, Minnema, Monique C, Seute, Tatjana, Cull, Gavin, Enting, Roelien H, van der Poel, Marjolein, Stevens, Wendy B C, Brandsma, Dieta, Beeker, Aart, Doorduijn, Jeanette K, Issa, Samar, van den Bent, Martin J, Bromberg, Jacoline E C

Obtenir text complet Obtenir text complet Obtenir text complet

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial per van der Meulen, Matthijs, Dirven, Linda, Habets, Esther J J, Bakunina, Katerina, Smits, Marion, Achterberg, Hakim C, Seute, Tatjana, Cull, Gavin, Schouten, Harry, Zijlstra, Josée M, Brandsma, Dieta, Enting, Roelien H, Beijert, Max, Taphoorn, Martin J B, van den Bent, Martin J, Issa, Samar, Doorduijn, Jeanette K, Bromberg, Jacoline E C

Obtenir text complet Obtenir text complet Obtenir text complet

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets per Yeung, David T., Osborn, Michael P., White, Deborah L., Branford, Susan, Braley, Jodi, Herschtal, Alan, Kornhauser, Michael, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark, Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K., Kwan, Yiu Lam, Trotman, Judith, Forsyth, Cecily J., Taper, John, Ross, David M., Beresford, Jennifer, Tam, Constantine, Mills, Anthony K., Grigg, Andrew P., Hughes, Timothy P.

Obtenir text complet Obtenir text complet Obtenir text complet